CVS Health Q3 2026 Results: Net Income $2.17 Billion on Revenue of $108.4 Billion
- US stocks
- Earnings
- Health Care

CVS Health (NYSE: CVS) reported GAAP revenue of $108.4 billion and GAAP net income attributable to the company of $2.17 billion for the third quarter of 2026, the three months ended 30 Sep 2026, and it said on 4 Nov 2026. GAAP diluted EPS was $1.68, and adjusted EPS, a company-defined measure, was $2.09.
Key highlights
- Revenue (GAAP): $108.4 billion, up 5.4% YoY and up 2.2% QoQ
- Net income (GAAP): $2.17 billion, against a loss of $3.98 billion a year earlier
- Diluted EPS (GAAP): $1.68, against a loss of $3.13 a year earlier
- Adjusted EPS (company-defined): $2.09, up from $1.60 a year earlier
- Adjusted operating income (company-defined): $4.19 billion, up 21.2% YoY
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 108,399.0 | 102,871.0 | +5.4% | 106,096.0 | +2.2% |
| 3,566.0 | -3,207.0 | n/a | 4,703.0 | -24.2% | |
| Operating margin | 3.29% | -3.12% | +6.41 pp | 4.43% | -1.14 pp |
| 2,172.0 | -3,975.0 | n/a | 2,979.0 | -27.1% | |
| Net income margin | 2.00% | -3.86% | +5.86 pp | 2.81% | -0.81 pp |
| Diluted EPS ($) | 1.68 | -3.13 | n/a | 2.31 | -27.3% |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
Against a year earlier, GAAP revenue rose 5.4% to $108.4 billion from $102.9 billion. Operating income was $3.57 billion, against a loss of $3.21 billion, and the table gives no year-on-year percentage for operating income or net income, where the year-ago figures were losses. Operating income was 3.3% of revenue, against a negative 3.1% a year earlier.
Against the previous quarter, revenue rose 2.2% and operating income fell 24.2%, from $4.70 billion to $3.57 billion. Diluted EPS fell 27.3%, to $1.68 from $2.31.
Adjusted figures exclude amortization and the Omnicare guarantee
The company's adjusted figures are company-defined measures that exclude items it names, including $425 million of intangible asset amortization, $193 million for the Omnicare guarantee and $13 million of acquisition-related integration costs in the third quarter. On that basis, adjusted operating income was $4.19 billion and adjusted income attributable to CVS Health was $2.70 billion. The company said the Omnicare guarantee is an estimated contingent guarantee liability recorded after bankruptcy court approval in August 2026.
Health Care Benefits adjusted operating income rose
Health Care Benefits adjusted operating income was $912 million, against $314 million a year earlier. The company said the increase was primarily driven by improved underlying performance in the Government business, and its medical benefit ratio was 91.3%, against 92.8%. Health Services adjusted operating income rose 2.7% to $2,106 million, and Pharmacy & Consumer Wellness rose 10.6% to $1,635 million, which the company attributes to core pharmacy strength and the Rite Aid asset acquisitions.
Guidance for 2026 was raised
The company now expects GAAP diluted EPS of at least $6.98, up from a previous range of $6.84 to $7.04, and Adjusted EPS of at least $8.20, up from $7.90 to $8.10. It also expects cash flow from operations of at least $15.5 billion, up from at least $11.5 billion.
The company tied the upward revision to its Health Care Benefits and Pharmacy & Consumer Wellness segments. It kept a cautious outlook for the rest of the year, pointing to elevated cost trends and possible macro pressure.
Inference
Weighted average diluted shares were 1,291 million, against 1,269 million a year earlier. Over the nine months to 30 Sep 2026 the company paid $2,578 million in dividends, against $2,552 million a year earlier.
The release does not say how much of the Omnicare guarantee will be paid, nor whether a dividend has been declared. The company said the sale of Omnicare's assets is probable in the fourth quarter of 2026.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

